Amgen Inc. (AMGN)
NASDAQ • Healthcare
January 21, 2026 at 19:16 UTC
Name
CEO
Website
Industry
Year Founded
Employees
Amgen Inc. is a biotechnology company focused on discovering, developing, and marketing medicines for serious illnesses across immunology, oncology, cardiometabolic disease, and other therapeutic areas. The company’s expertise spans biologics, targeted therapies, and biosimilars, supported by research platforms in protein engineering and human genetics. Commercial operations include physician education, patient access programs, and collaborations with health systems that emphasize safe and appropriate use of therapies. Amgen distributes products in North America, Europe, and additional regions through a mix of direct channels and partners. Positioned within the healthcare sector, the company’s work reflects the growing role of biotechnology in addressing complex medical needs and advancing precision approaches to treatment.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Amgen Inc.'s Technical Indicators Summary
Amgen's current price near $330 sits just below its 50-day simple moving average, which signals caution despite short- and medium-term averages indicating mild upward momentum. Momentum indicators, including RSI and CCI, suggest a balanced market with neither strong buying nor selling pressure, while the MACD also reflects a neutral stance. The average directional index remains low, pointing to weak trend strength, and volatility is moderate as shown by the ATR. Meanwhile, on-balance volume supports a slight bullish bias, though the absence of a VWAP reading limits intraday context. Overall, these mixed signals contribute to a neutral technical outlook for Amgen at this time.
| Indicator | Value |
|---|---|
RSI (14) | 52.32 |
Stochastic %K (14, 3, 3) | 46.67 |
CCI (20) | 28.45 |
WPR (14) | -50.89 |
Momentum (10) | 2.77 |
MFI | 44.90 |
MACD Level (12, 26) | 0.53 |
Bollinger Bands | $320.47 - $337.81 |
ATR (14) | $7.14 (2.16%) |
ADX (14) | 11.42 |
OBV | 88,470,400 |
Simple Moving Averages | $298.68 - $330.63(5 indicators) |
Exponential Moving Averages | $306.79 - $328.85(5 indicators) |
Get premium market insights delivered directly to your inbox.
At the open, AMGN slipped into a small -0.317% gap down, printing 329.95 compared with yesterday’s 331.00. From the bell, sector performance is mildly positive at 1.15%, a small boost for sentiment. Amgen's stock drops amid news of expanding its obesity strategy with new collaborations and dividend increase.
Price Change
from $331 close
+$7.49
Trading Volume
Below avg (2.8M)
772.9K
vs S&P 500 Today
Strong Outperformance
+6.63%
52-Week Position
Near highs
90.7%
Updated: January 21, 2026 at 15:37 UTC
Biopharma Leaders Map Growth at JPM 2026
January 13, 2026
Comprehensive Valuation Insights on Leading Stocks in Late 2025
November 30, 2025
Dow Hits Record High Amid Shutdown Optimism, Tech Stocks Slide
November 12, 2025